SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing increased selling pressure following the emergence and subsequent denial of acquisition rumors involving Lionsgate Studios, fueling community frustration over management's deal-making strategies. Investors are actively debating whether to capitalize on the recent price dip or scale out of positions, while many call for more aggressive execution of share buybacks to stabilize the stock.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc is trending as investors closely watch the upcoming AR spectacles unveiling, which is driving significant debate regarding the company's hardware strategy and potential for mass market adoption. Community members are actively split between those betting on the long-term value of the companys extensive patent portfolio and patent-heavy AR ecosystem, and those expressing skepticism over the product's premium price point and the leadership's ability to drive profitability.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor the company's aggressive legal move to reclaim commercial rights from Nippon Shinyaku, coupled with the strategic appointment of a veteran commercial officer ahead of the crucial FDA decision for deramiocel. The community is heavily focused on the potential for Capricor to launch the product independently, interpreting these developments as a major de-risking event that could unlock significant upside.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors digest news of a potential shift in corporate leadership and anticipation surrounding a binding tenant announcement. Community sentiment remains split between excitement over high-beta exposure to AI energy infrastructure and intense skepticism fueled by boardroom drama and past execution delays.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure shares are rallying following a leadership change at the FDA's gene therapy division, which investors believe will lead to more flexible regulatory reviews for its AMT-130 Huntington's disease treatment. The community is actively discussing the stock's potential for a significant turnaround, with many citing analyst upgrades and renewed optimism for accelerated approval pathways.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is currently attracting significant community attention as investors await clarity on the AXPAXLI NDA submission timeline following recent trial data. The stock is experiencing heightened volatility and intense debate, with many participants focused on the high institutional ownership and conflicting sentiment regarding the strength of its clinical results compared to existing standards of care.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as investors debate the impact of executive stock sales and sector-wide rotations against strong quarterly performance and enterprise growth. The community remains polarized, with some focusing on potential short-squeeze opportunities and bullish AI integration potential, while others express frustration over downward price pressure and institutional selling.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is seeing heightened interest as investors weigh its role in providing zinc-based, long-duration energy storage critical for AI data center and grid infrastructure against concerns surrounding its recent capital-raising and dilution efforts. While the community is actively debating the company's manufacturing scalability and the potential for a short squeeze given the significant short interest, sentiment remains divided between those betting on long-term institutional accumulation and those cautious of management's financial strategies.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is trending following a strategic partnership with Jazz Pharmaceuticals to develop T-cell engager therapies, alongside significant community debate regarding the company's long-term pipeline potential versus its recent market underperformance. Investors are closely monitoring upcoming clinical readouts and management commentary while navigating concerns about sentiment manipulation and the stock's volatility in the biotech sector.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is capturing significant investor attention as nuclear energy gains traction as a critical solution for powering AI data centers, fueled by speculation regarding major investment pledges from Japan and South Korea. While the community remains divided between long-term bullish sentiment over regulatory progress and skepticism regarding commercial execution, trading activity is intensified by anticipation of binding contracts and utility partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity

IQVIA Holdings gains from its vast healthcare data, AI-driven analytics & global IT infrastructure, supporting expansion and solid growth.

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wiley and IQVIA Release Cross-Sector Report on AIs Promise and Pressure Points Across Healthcare Value Chain

Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and...

ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?

ICLR looks cheap at 14.7x forward EPS versus peers, but 2026 guidance calls for lower revenue/EPS and a weak margin starting point.

ICLR Earnings Reset: What the Accounting Probe Changed

ICON plc details an accounting restatement, flags control weaknesses, and frames 2026 as a reset year amid mix-driven earnings swings.

Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQVIA (IQV) Up 3.2% Since Last Earnings Report: Can It Continue?

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQVIA Announces Pricing of Senior Notes

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the Issuer), priced an offering of 950,000,000 in aggregate principal amount of senior notes due 2033 (the Notes). The proceeds from the Notes offering will be used to refinance certain of the...

IQVIA Announces Offering of Senior Notes

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the Issuer), intends to raise 950,000,000 through an offering of senior notes due 2033 (the Notes). The proceeds from the Notes offering will be used to refinance certain of the Issuers existing...

Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission-critical information, technology solutions, and real-world evidence services to the company's life sciences clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial-related services. The Contract Sales and Medical Solutions segment offers healthcare provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1950 and is headquartered in Durham, NC.

IQVIA Holdings Inc

Retail Raves About IQVIA Holdings After Firm Raises Revenue, Profit Guidance

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$3.04	--	--	N/A
Q1 '26	$2.82	$2.90	2.96%	BEAT
Q4 '25	$3.39	$3.42	0.81%	BEAT
Q3 '25	$2.98	$3.00	0.84%	BEAT
Q2 '25	$2.77	$2.81	1.42%	BEAT

IQVIQVIA Holdings Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest IQV News